For patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced ...

The Phase III study saw the drug able to cut the risk of disease progression or death by 38% with imlunestrant alone, and ...

Data from a late-stage study shows that LLY's experimental oral drug benefited certain breast cancer patients when used as ...

Eli Lilly announces positive Phase III EMBER-3 trial results for imlunestrant in advanced breast cancer, showing a 38% ...

Imlunestrant, a next-generation SERD, improves progression-free survival in ER-positive advanced breast cancer patients ...

Imlunestrant, an oral SERD, significantly prolonged progression-free survival in patients with advanced ER+, HER2- breast ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 502.16% and ...

Eli Lilly announces a $15 billion share buyback, three times its previous largest program, highlighting strong financial ...

In a report released today, Steve Scala from TD Cowen maintained a Buy rating on Eli Lilly & Co (LLY – Research Report). The company’s ...

Alliance Foundation Trials, LLC (AFT) and Pfizer Inc. today announced results from the phase III PATINA trial demonstrating that the addition of palbociclib (IBRANCE) to current standard-of-care first ...

Months Before C.E.O.’s Killing, the Suspect Went Silent. Where Was He? New details are emerging about Luigi Mangione’s growing impatience with “a capitalist society” and his search for ...

The Israeli prime minister said its forces would remain in Syrian territory until “a new force” filled the vacuum. Secretary of State Antony J. Blinken was in Jordan for talks on the aftermath ...